EUVIMEDEUVIMED entdecken
Crossref

Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system

Patrick M Jedlowski iD, Jason P DuPont

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Patrick M Jedlowski und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, University of Arizona College of Medicine - Tucson, Tucson, Arizona, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Adverse Drug Reaction Reporting Systems, Immunosuppressive Agents, United States Food and Drug Administration. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sebaceous carcinoma (SC) is a rare skin cancer with significant associated morbidity and mortality. A known association exists between immunosuppression, in particular solid organ transplant patients (SOTR), and SC. However, the comparative reporting odds ratios (ROR) of different immunosuppressive medications and SC are incompletely defined.

Objectives

To examine the relationship between SC and medication exposure in the FDA adverse event reporting system (FAERS).

Methods

Case–control analyses were performed in FAERS from 1968 to 2021 to examine the reporting odds ratios (ROR) for SC.

Results

A total of 58 medication‐associated SC cases were identified. Immunosuppressant medication exposure was noted in 81% cases, with 20% total cases occurring in SOTR. Medications affecting the TNF‐ α ‐IL‐1‐IL‐2‐IL‐6 inflammatory axis were associated with elevated ROR for SC, including thalidomide (ROR 22.63, 95% CI 5.52–92.72), lenalidomide (ROR 10.86, 95% CI 4.93–23.94), cyclosporine, tacrolimus, tocilizumab, tofacitinib and ruxolitinib. Thirty per cent of cases of SC occurred with an associated haematologic malignancy or dyscrasia, including chronic lymphocytic leukaemia, non‐Hodgkin lymphoma and multiple myeloma.

Conclusions

SC is associated with exposure to immunosuppressive medications, especially in SOTR patients. A significant portion of cases with SC had an associated haematology malignancy, in particular multiple myeloma with exposure to lenalidomide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAdverse Drug Reaction Reporting SystemsImmunosuppressive AgentsUnited States Food and Drug AdministrationPharmacovigilanceNitrilesHumansUnited StatesMaleFemaleMiddle AgedAgedCase-Control StudiesHematologic NeoplasmsSebaceous Gland NeoplasmsImmunologic FactorsThalidomideAdultLenalidomidePyrazolesPyrimidinesTacrolimusAged, 80 and over

Substanzen

Immunosuppressive AgentsImmunologic FactorsThalidomideLenalidomideruxolitinibPyrazolesPyrimidinesTacrolimusNitriles

Autor:innen und Institutionen

  • Division of Dermatology, University of Arizona College of Medicine - Tucson, Tucson, Arizona, USA.

ORCID-Profile: Patrick M Jedlowski

Zitieren

APA

Jedlowski, P. M., & DuPont, J. P. (2024). Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19703

Vancouver

Jedlowski PM, DuPont JP. Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19703

BibTeX
@article{Jedlowski2024,
  author = {Jedlowski, Patrick M and DuPont, Jason P},
  title = {Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19703}
}
Kostenlos starten →